NASDAQ:PASG

Passage Bio (PASG) Stock Price, News & Analysis

Passage Bio logo
$3.98 -0.16 (-3.74%)
As of 10:57 AM Eastern
This is a fair market value price provided by Massive. Learn more.

About Passage Bio Stock (NASDAQ:PASG)

Advanced

Key Stats

Today's Range
$4.04
▼
$4.04
50-Day Range
$3.32
▼
$5.04
52-Week Range
$3.29
▼
$20.00
Volume
254 shs
Average Volume
58,270 shs
Market Capitalization
$12.83 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.25
Consensus Rating
Hold

Company Overview

Passage Bio is a clinical-stage biotechnology company developing gene therapies for rare, inherited central nervous system disorders. Its approach uses viral vectors to deliver genetic material intended to address the underlying causes of these diseases.

The company’s lead program, PBFT02, is being developed for frontotemporal dementia associated with mutations in the GRN gene. Passage Bio has also worked on gene therapy candidates for other rare neurological conditions, including Krabbe disease and GM1 gangliosidosis.

Based in Philadelphia, Passage Bio was established in collaboration with researchers at the University of Pennsylvania. Its work is focused on developing treatments for patients with serious genetic disorders that have limited therapeutic options.

AI Generated. May Contain Errors.

Passage Bio Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
52nd Percentile Overall Score

PASG MarketRank™: 
2.62008733624 of 5 stars

Passage Bio scored higher than 52% of companies evaluated by MarketBeat, and ranked 687th out of 1,704 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Passage Bio has received a consensus rating of Hold. The company's average rating score is 2.11, and is based on no strong buy ratings, 2 buy ratings, 6 hold ratings, and 1 sell rating.

  • Upside Potential

    Passage Bio has a consensus price target of $13.25, representing about 232.5% upside from its current price of $3.99.

  • Amount of Analyst Coverage

    Passage Bio has only been the subject of 1 research reports in the past 90 days.

  • Read more about Passage Bio's stock forecast and price target.
  • Earnings Growth

    Earnings for Passage Bio are expected to grow in the coming year, from ($7.75) to ($3.91) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Passage Bio is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Passage Bio is -0.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Passage Bio has a P/B Ratio of 199.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    1.62% of the float of Passage Bio has been sold short.
  • Short Interest Ratio / Days to Cover

    Passage Bio has a short interest ratio ("days to cover") of 3.99, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Passage Bio has recently decreased by 28.10%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Passage Bio does not currently pay a dividend.

  • Dividend Growth

    Passage Bio does not have a long track record of dividend growth.

  • News Sentiment

    Passage Bio has a news sentiment score of -0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Healthcare companies.
  • MarketBeat Follows

    2 people have added Passage Bio to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Passage Bio insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    4.90% of the stock of Passage Bio is held by insiders.

  • Percentage Held by Institutions

    53.48% of the stock of Passage Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Passage Bio's insider trading history.
Receive PASG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Passage Bio and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

PASG Stock News Headlines

Passage Bio (PASG) Projected to Post Quarterly Earnings on Monday
Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
See More Headlines

PASG Stock Analysis - Frequently Asked Questions

Passage Bio's stock was trading at $11.80 at the beginning of 2026. Since then, PASG shares have decreased by 66.2% and is now trading at $3.9850.

Passage Bio, Inc. (NASDAQ:PASG) posted its quarterly earnings data on Tuesday, November, 10th. The company reported ($1.47) earnings per share for the quarter, hitting analysts' consensus estimates of ($1.47).

Shares of Passage Bio reverse split before market open on Monday, July 14th 2025.The 1-20 reverse split was announced on Thursday, July 10th 2025. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 11th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Passage Bio (PASG) raised $204 million in an initial public offering (IPO) on Friday, February 28th 2020. The company issued 12,000,000 shares at $16.00-$18.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO and Chardan was co-manager.

Passage Bio's top institutional shareholders include Nantahala Capital Management LLC (3.96%). Insiders that own company stock include Lynx1 Capital Management Lp, Orbimed Advisors Llc, William Chou, Mark S Forman and Kathleen Borthwick.
View institutional ownership trends
.

Shares of PASG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Passage Bio investors own include Editas Medicine (EDIT), Gossamer Bio (GOSS), Cabaletta Bio (CABA), Precision BioSciences (DTIL), Black Diamond Therapeutics (BDTX), LogicBio Therapeutics (LOGC) and HOOKIPA Pharma (HOOK).

Company Calendar

Last Earnings
11/10/2026
Today
11/19/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:PASG
CIK
1787297
Fax
N/A
Employees
24
Year Founded
2018

Price Target and Rating

High Price Target
$23.00
Low Price Target
$7.00
Potential Upside/Downside
+232.5%
Consensus Rating
Hold
Rating Score (0-4)
2.11
Research Coverage
9 Analysts

Profitability

EPS (Trailing Twelve Months)
($10.35)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$45.52 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-377.94%
Return on Assets
-91.44%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.00
Quick Ratio
1.00

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.02 per share
Price / Book
199.25

Miscellaneous

Outstanding Shares
3,220,000
Free Float
3,060,000
Market Cap
$12.83 million
Optionable
No Data
Beta
1.51

Social Links

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:PASG) was last updated on 11/19/2026 by MarketBeat.com Staff.
From Our Partners